Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase iII children's oncology group Trial AAML0531

Journal of Clinical Oncology

Volumn 32, Issue 27, 2014, Pages 3021-3032

  Gamis, Alan S ^a   Alonzo, Todd A ^b   Meshinchi, Soheil ^e   Sung, Lillian ⁿ   Gerbing, Robert B ^c   Raimondi, Susana C ^g   Hirsch, Betsy A ^h   Kahwash, Samir B ⁱ   Heerema McKenney, Amy ^d   Winter, Laura ^f   Glick, Kathleen ^l   Davies, Stella M ^j   Byron, Patti ^o   Smith, Franklin O ^k   Aplenc, Richard ^m  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Children's Oncology Group   (Liberia)

^d STANFORD UNIVERSITY   (United States)

^e USA   (United States)

^f SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ NATIONWIDE CHILDREN S HOSPITAL   (United States)

^j CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^k UNIVERSITY OF CINCINNATI   (United States)

^l Maine Children's Cancer Program Scarborough   (United States)

^m CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

ⁿ HOSPITAL FOR SICK CHILDREN   (Canada)

^o BC CHILDREN S HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD33 ANTIGEN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; MITOXANTRONE; RECOMBINANT ASPARAGINASE; AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; GEMTUZUMAB; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; ADOLESCENT; ADOLESCENT DISEASE; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CHILD; CHILDHOOD LEUKEMIA; DISEASE FREE SURVIVAL; ESCHERICHIA COLI; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STEM CELL TRANSPLANTATION; CANADA; CLINICAL TRIAL; CONTROLLED STUDY; EPIDEMIOLOGY; INDUCTION CHEMOTHERAPY; INFANT; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANADA; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; INFANT; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; RECURRENCE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84907192040     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.3628     Document Type: Article

References (48)

1. Smith MA, Seibel NL, Altekruse SF, et al.: Outcomes for children and adolescents with cancer: Challenges for the twenty-first century. J Clin Oncol 28:2625-2634, 2010
2. Gamis AS, Alonzo TA, Perentesis JP, et al.: Children's Oncology Group's 2013 blueprint for research: Acute myeloid leukemia. Pediatr Blood Cancer 60:964-971, 2013
3. Woods WG, Kobrinsky N, Buckley JD, et al.: Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group. Blood 87:4979-4989, 1996
4. Lange BJ, Smith FO, Feusner J, et al.: Outcomes in CCG-2961, a Children's Oncology Group phase 3 trial for untreated pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Blood 111:1044-1053, 2008
5. Woods WG, Neudorf S, Gold S, et al.: A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 97:56-62, 2001
6. Stevens RF, Hann IM, Wheatley K, et al.: Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: Results of the United Kingdom Medical Research Council's 10th AML trial-MRC Childhood Leukaemia Working Party. Br J Haematol 101:130-140, 1998
7. Gibson BE, Webb DK, Howman AJ, et al.: Results of a randomized trial in children with acute myeloid leukaemia: Medical research council AML12 trial. Br J Haematol 155:366-376, 2011
8. Bernstein I: CD33 as a target for selective ablation of acute myeloid leukemia. Clin Lymphoma 2:S9-S11, 2002 (suppl 1)
9. Walter RB, Appelbaum FR, Estey EH, et al.: Acute myeloid leukemia stem cells and CD33- targeted immunotherapy. Blood 119:6198-6208, 2012
10. Ricart AD: Antibody-drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 17:6417- 6427, 2011
11. Arceci RJ, Sande J, Lange B, et al.: Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33 acute myeloid leukemia. Blood 106:1183-1188, 2005
12. Sievers EL, Appelbaum FR, Spielberger RT, et al.: Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93:3678-3684, 1999
13. Zwaan CM, Reinhardt D, Corbacioglu S, et al.: Gemtuzumab ozogamicin: First clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood 101:3868-3871, 2003
14. Sievers EL, Larson RA, Stadtmauer EA, et al.: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19:3244-3254, 2001
15. Aplenc R, Alonzo TA, Gerbing RB, et al.: Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: A report from the Children's Oncology Group. J Clin Oncol 26:2390-2395, 2008
16. Cooper TM, Franklin J, Gerbing RB, et al.: AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the Children's Oncology Group. Cancer 118:761-769, 2012
17. Kell WJ, Burnett AK, Chopra R, et al.: A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 102: 4277-4283, 2003
18. Bross PF, Beitz J, Chen G, et al.: Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res 7:1490-1496, 2001
19. Petersdorf SH, Kopecky KJ, Slovak M, et al.: A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121: 4854-4860, 2013
20. Rowe JM, Löwenberg B: Gemtuzumab ozogamicin in acute myeloid leukemia: A remarkable saga about an active drug. Blood 121:4838-4841, 2013
21. Castaigne S, Pautas C, TerréC, et al.: Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA- 0701): A randomised, open-label, phase 3 study. Lancet 379:1508-1516, 2012
22. Burnett AK, Hills RK, Milligan D, et al.: Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial. J Clin Oncol 29:369-377, 2011
23. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302, 2002
24. van der Velden VH, Boeckx N, Jedema I, et al.: High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 18:983-988, 2004
25. Chevallier P, Roland V, MahéB, et al.: Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33 primary resistant or relapsed acute myeloid leukemia. Leuk Res 29:1003-1007, 2005
26. Meshinchi S, Alonzo TA, Stirewalt DL, et al.: Clinical implications of FLT3 mutations in pediatric AML. Blood 108:3654-3661, 2006
27. Wheatley K, Burnett AK, Goldstone AH, et al.: A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial: United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 107:69-79, 1999
28. Kottaridis PD, Gale RE, Frew ME, et al.: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752-1759, 2001
29. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
30. Kalbfleisch JD, Prentice RL: The statistical analysis of failure time data: 1980. New York, NY, John Wiley & Sons, 1980
31. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
32. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
33. Burnett AK, Russell NH, Hills RK, et al.: Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 30:3924-3931, 2012
34. Fernandez HF, Sun Z, Yao X, et al.: Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361:1249-1259, 2009
35. Löwenberg B, Ossenkoppele GJ, van Putten W, et al.: High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361: 1235-1248, 2009
36. Hills RK, Petersdorf S, Estey EH, et al.: The addition of gemtuzumab ozogamicin (GO) to induction chemotherapy reduces relapse and improves survival in patients without adverse risk karyotype: Results of an individual patient meta-analysis of the five randomised trials. Blood 122:356, 2013
37. Gibson BE, Wheatley K, Hann IM, et al.: Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 19:2130-2138, 2005
38. Webb DK, Wheatley K, Harrison G, et al.: Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial: MRC Childhood Leukaemia Working Party. Leukemia 13:25-31, 1999
39. Burnett AK, Goldstone A, Hills RK, et al.: Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol 31:1293-1301, 2013
40. Pollard JA, Alonzo TA, Loken M, et al.: Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood 119:3705-3711, 2012
41. Forman SJ, Rowe JM: The myth of the second remission of acute leukemia in the adult. Blood 121:1077-1082, 2013
42. Burnett AK, Russell NH, Hills RK, et al.: Optimization of chemotherapy for younger patients with acute myeloid leukemia: Results of the Medical Research Council AML15 Trial. J Clin Oncol 31: 3360-3368, 2013
43. Hasle H, Abrahamsson J, Forestier E, et al.: Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: Results from NOPHO-AML 2004. Blood 120:978- 984, 2012
44. Wadleigh M, Richardson PG, Zahrieh D, et al.: Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 102:1578-1582, 2003
45. O'Hear C, Inaba H, Pounds S, et al.: Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer 119:4036-4043, 2013
46. Walter RB, Buckley SA, Pagel JM, et al.: Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 122:1813-1821, 2013
47. Horan JT, Meshinchi S, Loken MR, et al.: Impact of residual disease on survival in pediatric patients receiving allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission. Blood 122:65, 2013
48. Kung Sutherland MS, Walter RB, Jeffrey SC, et al.: SGN-CD33A: A novel CD33-targeting antibodydrug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 122:1455-1463, 2013